Key result
Beta-blockers might be well tolerated and have a beneficial effect in COPD patients with concurrent cardiovascular disease.
Why the study?
Safety concerns have been raised regarding the use of beta-blockers in patients with COPD and concurrent cardiovascular disease.
Are beta-blockers safe and beneficial in COPD patients with concurrent cardiovascular disease?
Are beta-blockers safe and beneficial in COPD patients with concurrent cardiovascular disease?
This review suggests that beta-blockers are well-tolerated and potentially beneficial in patients with COPD and concurrent cardiovascular disease, challenging historical safety concerns.
May support beta-blocker use in COPD with CVD; leaves open confirmation by RCTs.
Approximately half a century has passed since the discovery of beta-blockers. Then, their prime therapeutic purpose was to treat angina and cardiac arrhythmias; nowadays, beta-blockers' usage and effectiveness are extended to treat other cardiovascular diseases, such as hypertension, congestive heart failure, and coronary artery disease. Safety concerns were raised about beta- blockers and their use for chronic obstructive pulmonary disease (COPD) patients with concurrent cardiovascular disease. After thorough research of the literature, this review summarizes the evidence proving that beta-blockers not only might be well tolerated in COPD patients, but they might also have a beneficial effect in this group of patients.
No takes yet. Share an insight, caveat, or question.
Baou et al. (2020) conducted a review in Chronic Obstructive Pulmonary Disease (COPD) with concurrent cardiovascular disease. Beta-blockers was evaluated. Beta-blockers might be well tolerated and have a beneficial effect in COPD patients with concurrent cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: